Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma

NCT02490800 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT02490800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02490800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 1/2
Overall status
Completed
Start date
May 20, 2015
Completion date
November 24, 2022
Enrollment
72 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms